Genetic testing company Natera (NASDAQ:NTRA). reported Q3 CY2025 results beating Wall Street’s revenue expectations , with sales up 34.7% year on year to $592.2 million. The company’s full-year revenue guidance of $2.22 billion at the midpoint came in 6.1% above analysts’ estimates. Its GAAP loss of $0.64 per share was 74.5% below analysts’ consensus estimates. Is now the time to buy Natera? Find out in our full research report. Natera (NTRA) Q3 CY2025 Highlights: Revenue: $592.2 million vs analyst esti ...